CRNX
Crinetics Pharmaceuticals Inc.
$36.78
-$0.02(-0.05%)
46
Overall
60
Value
33
Tech
47
Quality
Market Cap
$3.68B
Volume
716.51K
52W Range
$25.83 - $57.99
Target Price
$82.93
Order:
Income Statement
| Metric | Trend | Chart | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||
| Total Revenue | $2.4M | $1.2M | $71.0K | $1.1M | $4.7M | $4.0M | $1.0M | $7.7M | ||
| Total Revenue | $2.4M | $1.2M | $71.0K | $1.1M | $4.7M | $4.0M | $1.0M | $7.7M | ||
| COST OF GOODS SOLD | ||||||||||
| Cost of Revenue | -- | -- | -- | -- | -- | -- | -- | $1.1M | ||
| GROSS PROFIT | ||||||||||
| Gross Profit | $2.4M | $1.2M | $71.0K | $1.1M | $4.7M | $4.0M | $1.0M | $6.6M | ||
| OPERATING EXPENSES | ||||||||||
| Operating Expenses | $31.3M | $55.0M | $75.0M | $108.8M | $172.6M | $226.6M | $339.9M | $523.4M | ||
| Research & Development | $24.5M | $41.5M | $57.0M | $84.3M | $130.2M | $168.5M | $240.2M | $332.1M | ||
| Research Expense | $24.5M | $41.5M | $57.0M | $84.3M | $130.2M | $168.5M | $240.2M | $332.1M | ||
| Selling, General & Administrative | $6.7M | $13.5M | $18.0M | $24.5M | $42.4M | $58.1M | $99.7M | $191.3M | ||
| Selling & Marketing Expenses | -- | -- | -- | -- | -- | $-58.1M | $-99.7M | -- | ||
| General & Administrative Expenses | $6.7M | $13.5M | $18.0M | $24.5M | $42.4M | $58.1M | $99.7M | $191.3M | ||
| Salaries & Wages | $-2.3M | $6.3M | $10.4M | $17.4M | $28.3M | -- | $69.4M | -- | ||
| Depreciation & Amortization | -- | $900.0K | $900.0K | $900.0K | $1.0M | $1.1M | $2.8M | -- | ||
| Depreciation & Amortization | -- | $900.0K | $900.0K | $900.0K | $1.0M | -- | $2.8M | -- | ||
| Other Operating Expenses | $153.0K | $-472.0K | $-369.0K | $-495.0K | $-1.7M | -- | $-3.8M | -- | ||
| OPERATING INCOME | ||||||||||
| Operating income | $-28.9M | $-53.8M | $-75.0M | $-107.7M | $-167.9M | $-222.6M | $-338.9M | $-516.8M | ||
| EBITDA | $-27.1M | $-50.8M | $-74.0M | $-106.8M | $-163.1M | $-214.2M | $-293.2M | $-458.2M | ||
| NON-OPERATING ITEMS | ||||||||||
| Intinc | $1.7M | $3.5M | $991.0K | $157.0K | $4.3M | $13.4M | $41.4M | $52.0M | ||
| Net Non-Operating Interest Income/Expense | $1.7M | $3.5M | $991.0K | $157.0K | $4.3M | $13.4M | $41.4M | $52.0M | ||
| Gain on Sale of Securities | -- | -- | $26.0M | $-86.0M | $-86.0K | -- | $51.0K | -- | ||
| Other Income/Expense | -- | $50.0K | $-150.0K | $86.0M | $-353.0K | $5.2M | $989.0K | $357.0K | ||
| Other Special Charges | -- | $-50.0K | $150.0K | $-96.0K | -- | -- | $-519.0K | $-357.0K | ||
| PRE-TAX INCOME | ||||||||||
| EBIT | $-27.1M | $-50.4M | $-75.0M | $-107.7M | $-164.0M | $-215.3M | $-299.0M | $-465.1M | ||
| Pre-Tax Income | $-27.1M | $-50.4M | $-73.8M | $-107.5M | $-163.9M | $-214.4M | $-297.9M | $-465.1M | ||
| INCOME TAX | ||||||||||
| Tax Provision | $-547.0K | $-3.4M | $-4.9M | $-7.1M | $-128.0K | $-797.0K | $-593.0K | $180.0K | ||
| NET INCOME | ||||||||||
| Net Income | $-27.1M | $-50.4M | $-73.8M | $-107.6M | $-163.9M | $-214.5M | $-298.4M | $-465.3M | ||
| Net Income (Continuing Operations) | $-27.1M | $-50.4M | $-73.8M | $-107.6M | $-163.9M | $-214.5M | $-298.4M | $-465.3M | ||
| Net Income (Discontinued Operations) | $-27.1M | $-50.4M | $-73.8M | $-107.6M | $-163.9M | $-214.5M | $-298.4M | $-465.3M | ||
| Net Income (Common Stockholders) | $-27.1M | $-50.4M | $-73.8M | $-107.6M | $-163.9M | $-214.5M | $-298.4M | $-465.3M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | $-460.5M | ||
| TOTALS | ||||||||||
| Total Expenses | $31.3M | $55.0M | $75.0M | $108.8M | $172.6M | $226.6M | $339.9M | $524.5M | ||
| SHARE & EPS DATA | ||||||||||
| Average Shares Outstanding | $12.1M | $24.2M | $30.4M | $38.4M | $52.0M | $58.1M | $80.8M | $94.1M | ||
| Average Shares Outstanding (Diluted) | $12.1M | $24.2M | $30.4M | $38.4M | $52.0M | $58.1M | $80.8M | $94.1M | ||
| Shares Outstanding | $24.1M | $24.6M | $33.0M | $47.8B | $53.9M | $69.6M | $93.0M | $104.7M | ||
| Basic EPS | -- | $-2.09 | $-2.42 | $-2.8 | $-3.15 | $-3.69 | $-3.69 | $-4.95 | ||
| Basic EPS (Continuing Operations) | -- | $-2.09 | $-2.42 | $-2.8 | $-3.15 | $-3.69 | $-3.69 | $-4.95 | ||
| Diluted EPS | $-2.23 | $-2.09 | $-2.42 | $-2.8 | $-3.15 | $-3.69 | $-3.69 | $-4.95 | ||
| Diluted EPS (Continuing Operations) | $-2.23 | -- | -- | -- | $-3.15 | $-3.69 | $-3.69 | $-4.95 | ||
| OTHER METRICS | ||||||||||
| Earnings from equity interest | -- | -- | -- | -- | $-1.0M | $-5.2M | $-470.0K | -- | ||
| Earnings From Equity Interest Net Of Tax | -- | -- | -- | -- | $-1.0M | $-5.2M | $-470.0K | -- | ||
| Other Gand A | $6.7M | $13.5M | $18.0M | $24.5M | $42.4M | $58.1M | $99.7M | $191.3M | ||
| Rent And Landing Fees | $-600.0K | -- | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CRNX | $36.78 | -0.1% | 716.51K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Crinetics Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW